

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-11. (canceled)

12. (currently amended) A method of treatment of a human patient for cancer, comprising administering Ecteinascidin-743 (Et 743) at a dose level of 1500 ~~500 to 1650~~ micrograms/m² body surface area in cycles by intravenous infusion at intervals of 3 to 4 weeks ~~about 1-6 weeks~~ with an infusion time of ~~about 2 to about~~ 24 hours wherein said treatment results in a reduction in tumor size.

13-27. (canceled)

28. (currently amended) A method according to ~~claim 27~~ claim 12, wherein the patient is allowed to recover for the remainder of the cycle.

29. (currently amended) A method according to claim 12 ~~claim 28~~, wherein the cycle is 3 ~~or 4~~ weeks.

30. (currently amended) A method according to ~~one of claims 12, 17, or~~ claim 29, wherein the cancer is soft tissue sarcoma, melanoma, leiomyosarcoma, colon stromal sarcoma, gastric stromal sarcoma, osteosarcoma, liposarcoma, breast cancer, ovarian cancer, mesothelioma, or ocular melanoma.

31. (previously presented) A method according to claim 30, wherein the cancer has metastasized.

32. (previously presented) A method according to claim 30, wherein the patient has been previously treated for cancer with chemotherapy.

33. (currently amended) A method according to ~~one of claims 12, 17, or claim~~ claim 29, further comprising the administration of at least one additional drug.

34. (previously presented) A method according to claim 33, wherein the at least one additional drug is selected from: a) a drug with an antimitotic effect; b) an antimetabolite drug; c) an alkylating agent or nitrogen mustard; d) a drug which targets DNA; e) a drug which targets topoisomerase; f) a hormone or a hormone agonist or antagonist; g) a drug which targets signal transduction in tumor cells; h) an alkylating drug; i) a drug potentially affecting metastasis of tumors; j) a gene therapy or antisense agent; k) an antibody therapeutic; l) a bioactive compound of marine origin; m) a steroid analog; n) an anti-inflammatory drug; or o) an anti-emetic drug.

35. (previously presented) A method according to claim 33, wherein the at least one additional drug is dexamethasone.

36. (new) A method according to claim 30, wherein the cancer is soft tissue sarcoma.

37. (new) A method according to claim 30, wherein the cancer is leiomyosarcoma.

38. (new) A method according to claim 30, wherein the cancer is liposarcoma.

39. (new) A method according to claim 30, wherein the cancer is breast cancer.

40. (new) A method according to claim 30, wherein the cancer is ovarian cancer.

41. (new) A method according to claim 12, wherein the cycle is 4 weeks.

42. (new) A method according to claim 41, wherein the cancer is soft tissue sarcoma, melanoma, leiomyosarcoma, colon stromal sarcoma, gastric stromal sarcoma, osteosarcoma, liposarcoma, breast cancer, ovarian cancer, mesothelioma, or ocular melanoma.

43. (new) A method according to claim 42, wherein the cancer has metastasized.

44. (new) A method according to claim 42, wherein the patient has been previously treated for cancer with chemotherapy.

45. (new) A method according to claim 41, further comprising the administration of at least one additional drug.

46. (new) A method according to claim 45, wherein the at least one additional drug is selected from: a) a drug with an antimitotic effect; b) an antimetabolite drug; c) an alkylating agent or nitrogen mustard; d) a drug which targets DNA; e) a drug which targets topoisomerase; f) a hormone or a hormone agonist or antagonist; g) a drug which targets signal transduction in tumor cells; h) an alkylating drug; i) a drug potentially affecting metastasis of tumors; j) a gene therapy or antisense agent; k) an antibody therapeutic; l) a bioactive compound of marine origin; m) a steroid analog; n) an anti-inflammatory drug; or o) an anti-emetic drug.

47. (new) A method according to claim 45, wherein the at least one additional drug is dexamethasone.

48. (new) A method according to claim 42, wherein the cancer is soft tissue sarcoma.

49. (new) A method according to claim 42, wherein the cancer is leiomyosarcoma.

50. (new) A method according to claim 42, wherein the cancer is liposarcoma.

51. (new) A method according to claim 42, wherein the cancer is breast cancer.

52. (new) A method according to claim 42, wherein the cancer is ovarian cancer.